Multimodal therapy of ADHD in health data claims


Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurocognitive developmental disorders in childhood and adolescence. ADHD is associated with a variety of complications over the entire life cycle. These include psychiatric comorbidities (e.g., substance abuse), social impairments (e.g., marital and child-rearing problems), school and occupational failure (e.g., unemployment) and risky behavior (e.g., increased incidence of traffic accidents). The associated costs of ADHD—for the statutory health insurances (SHI) alone—have been estimated at over 260 million Euros per year for Germany. Therefore, an early and effective treatment strategy for patients with ADHD is essential.

The multimodal treatment approach recommended in national and international ADHD guidelines includes the use of drugs (e.g., methylphenidate) as well as psychosocial treatments such as psychotherapy. Currently, there are hardly any population-based studies that investigate the extent to which multimodal treatment approaches are used in children and adolescents diagnosed with ADHD.
This research project therefore evaluates which proportion of children and adolescents with ADHD receives multimodal treatment.

Based on claims data, low-threshold medical consultations of a psychotherapeutic nature are taken into account in addition to psychotherapeutic services according to the so-called Psychotherapy guideline.

Funding period

Begin:   October 2019
End:   September 2020


  • Friede Springer Foundation


PD Dr. rer. nat. Oliver Riedel